Table 1.

Pharmacodynamic and structural categories associate with frequency of report of undesired events for clinically available hMOR ligands^#

Undesired events associated with	Type of side effect	Preferred term	R square	p-value
Functional categories defined by Log(τ)–Emax–Log(τ/KA)	Gastrointestinal/nutrition	Cachexia	0.66	0.05
		Faecaloma	0.86	0.01
		Gastrointestinal motility disorder	0.81	0.01
	Respiratory events	Respiratory depression	0.62	0.11
		Respiratory rate decreased	0.60	0.13
	Sleep disorder	Somnolence	0.60	0.12
Functional categories defined by Log(τ)-Emax	Gastrointestinal/nutrition	Cachexia	0.66	0.05
		Faecaloma	0.92	0.00
		Gastrointestinal motility disorder	0.62	0.06
	Respiratory events	Hypoventilation	0.68	0.08
		Oxygen saturation decreased	0.61	0.12
		Respiratory depression	0.78	0.05
		Respiratory rate decreased	0.69	0.08
	Sleep disorder	Somnolence	0.75	0.06
Structural categories	Respiratory events	Hypopnoea	0.65	0.10
		Yawning	0.79	0.04
	Neuropsychiatric	Withdrawal syndrome	0.74	0.06
	Change in drug response	Analgesic drug level increased	0.70	0.08
		Drug effect decreased	0.64	0.10
		Drug effect increased	0.90	0.01
		Therapeutic response increased	0.89	0.02
		Therapeutic response decreased	0.74	0.06
	Pain	Breakthrough pain	0.69	0.08
		Complex regional pain syndrome	0.64	0.11
	Itching	Pruritus generalized	0.86	0.02
	Others	Therapy cessation	0.76	0.05

^#Only significant correlations, and correlations that explained 60% or more of the variance were considered; full information in Supplementary Data 2. Similarity and SD gamma scores for Buprenorphine, Fentanyl, Morphine, Oxycodone, and Tramadol were used to establish correlations. Loperamide was additionally included in correlations for gastrointestinal reports. Source data provided in Supplementary Data 2 and source data files